PURE BIOLOGICS ZY -10
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts r… Read more
Market Cap & Net Worth: PURE BIOLOGICS ZY -10 (PQB)
PURE BIOLOGICS ZY -10 (F:PQB) has a market capitalization of $3.03 Million (€2.95 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #36215 globally and #4403 in its home market, demonstrating a -46.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PURE BIOLOGICS ZY -10's stock price €0.26 by its total outstanding shares 11330248 (11.33 Million).
PURE BIOLOGICS ZY -10 Market Cap History: 2021 to 2026
PURE BIOLOGICS ZY -10's market capitalization history from 2021 to 2026. Data shows change from $186.08 Million to $3.03 Million (-59.68% CAGR).
PURE BIOLOGICS ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PURE BIOLOGICS ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PQB by Market Capitalization
Companies near PURE BIOLOGICS ZY -10 in the global market cap rankings as of March 18, 2026.
Key companies related to PURE BIOLOGICS ZY -10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PURE BIOLOGICS ZY -10 Historical Marketcap From 2021 to 2026
Between 2021 and today, PURE BIOLOGICS ZY -10's market cap moved from $186.08 Million to $ 3.03 Million, with a yearly change of -59.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.03 Million | -63.17% |
| 2025 | €8.23 Million | -83.92% |
| 2024 | €51.17 Million | +39.46% |
| 2023 | €36.69 Million | -31.34% |
| 2022 | €53.44 Million | -71.28% |
| 2021 | €186.08 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PURE BIOLOGICS ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.03 Million USD |
| MoneyControl | $3.03 Million USD |
| MarketWatch | $3.03 Million USD |
| marketcap.company | $3.03 Million USD |
| Reuters | $3.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.